European Urology Oncology

Slides:

Advertisements

Similar presentations

The PSA Era is not Over for Prostate Cancer

Advertisements

Volume 61, Issue 6, Pages (June 2012)

The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients

Prostate Cancer: Highlights from 2006

Volume 70, Issue 4, Pages (October 2016)

Volume 53, Issue 5, Pages (May 2008)

Volume 64, Issue 4, Pages (October 2013)

Volume 51, Issue 4, Pages (April 2007)

Volume 71, Issue 5, Pages (May 2017)

European Urology Oncology

Volume 63, Issue 4, Pages e53-e56 (April 2013)

Volume 67, Issue 2, Pages (February 2015)

Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.

Volume 68, Issue 5, Pages (November 2015)

What is New in Hormone Therapy for Prostate Cancer in 2007?

Volume 53, Issue 4, Pages (April 2008)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 68, Issue 3, Pages (September 2015)

Volume 184, Issue 4, Pages (October 2010)

Volume 71, Issue 6, Pages (June 2017)

European Urology Oncology

Laurent Boccon-Gibod European Urology Supplements

Volume 64, Issue 6, Pages (December 2013)

Volume 73, Issue 2, Pages (February 2018)

The PSA Era is not Over for Prostate Cancer

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Volume 61, Issue 6, Pages (June 2012)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Rectal Injury During Radical Prostatectomy: Focus on Robotic Surgery

RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer Matthew R. Smith European Urology Supplements

Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care Fred Saad, Carl Olsson, Claude C. Schulman

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Optimising Hormone Therapy in Advanced Disease

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer– specific Mortality: Competition Between Age and Time to Biochemical Failure

European Urology Oncology

Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study Oskar Bergengren, Hans Garmo, Ola Bratt, Lars Holmberg,

European Urology Oncology

What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,

European Urology Oncology

European Urology Oncology

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Long-Term Hormonal Therapy: Who Would Benefit?

European Urology Oncology

Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer Felix Preisser, Michele Marchioni, Sebastiano.

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results.

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study Andrew M. Erickson, Stefano Luzzago, Axel.

Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis Joseph Sargon Joseph, Vincent.

Alex K. Bryant, BS, Robert C. Mundt, HSDG, Ajay P. Sandhu, MD, James J

European Urology Oncology

Axel Heidenreich European Urology Supplements

European Urology Oncology

European Urology Oncology

Highlighting Unmet Needs: Real Patients, Difficult Choices

European Urology Oncology

Volume 53, Issue 6, Pages (June 2008)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Axel Heidenreich European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

Salvage Local Treatments After Focal Therapy for Prostate Cancer

European Urology Oncology

European Urology Oncology

European Urology Oncology

European Urology Oncology

Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood Jan F.M. Verbeek,

Presentation transcript:

European Urology Oncology Association between Radical Prostatectomy and Survival in Men with Clinically Node- positive Prostate Cancer Reith R. Sarkar, Alex K. Bryant, J. Kellogg Parsons, Stephen T. Ryan, A. Karim Kader, Christopher J. Kane, Rana R. McKay, Ajay Sandhu, James D. Murphy, Brent S. Rose European Urology Oncology DOI: 10.1016/j.euo.2018.09.015 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Unadjusted curves for cumulative prostate cancer–specific and all-cause mortality. Prostate cancer–specific mortality for (A) nondefinitive therapy versus radical prostatectomy (RP) and (B) androgen deprivation therapy (ADT)/radiotherapy (RT) versus RP. All-cause mortality for (C) nondefinitive therapy versus RP and (D) ADT/RT versus RP. Gray's test for equality of cumulative incidence functions was used to calculate the p values. Dashed lines indicate the confidence intervals. European Urology Oncology DOI: (10.1016/j.euo.2018.09.015) Copyright © 2018 European Association of Urology Terms and Conditions